Produktbild: Risk Factors for Psychosis

Risk Factors for Psychosis Paradigms, Mechanisms, and Prevention

119,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

25.02.2020

Herausgeber

Thompson Andrew + weitere

Verlag

Elsevier Science & Technology

Seitenzahl

456

Maße (L/B/H)

23,1/18,8/2,3 cm

Gewicht

910 g

Sprache

Englisch

ISBN

978-0-12-813201-2

Beschreibung

Portrait

Dr Andrew Thompson is a Principal Research Fellow and Associate Professor at Orygen, the Centre for Youth Mental Health at the University of Melbourne, Australia. He is the lead psychiatrist for the EPPIC early psychosis service and the National headspace Early Psychosis program in Australia and is currently head of clinical psychosis research at Orygen. He also retains a position as Associate Professor at the University of Warwick in the UK.

Andrew trained in medicine at the University of Oxford and London and in psychiatry in Nottingham and Bristol. He has an MD in clinical psychiatry from the University of London. He has worked in early psychosis practice and research for over 15 years in both the UK and Australia. He was previously clinical lead for the PACE at risk for psychosis clinic in Melbourne and has been involved in a number of research projects through this clinic and through his work at the University of Bristol and the University of Warwick.

Andrew’s research interests include clinical risk factors for the development of psychosis and psychotic symptoms, novel treatments (including technology) in emerging or early psychosis, predictors of outcome in early psychosis and systems of care and prevention approaches in youth mental health.

Dr Matthew Broome is a Senior Clinical Research Fellow at the Department of Psychiatry, University of Oxford, and a Consultant Psychiatrist at the Early Intervention in Psychosis Service, Oxford. He trained in medicine at the University of Birmingham and in Psychiatry at the Maudsley hospital (where he worked at the at risk for psychosis clinic (OASIS). He has previously been a Lecturer at the Institute of Psychiatry and an Associate Clinical Professor at The University of Warwick. He has previously edited books on subjects such as phenomenology and the interface between psychiatry and philosophy and has published over 100 research papers mostly relating to at risk for psychosis groups.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

25.02.2020

Herausgeber

Verlag

Elsevier Science & Technology

Seitenzahl

456

Maße (L/B/H)

23,1/18,8/2,3 cm

Gewicht

910 g

Sprache

Englisch

ISBN

978-0-12-813201-2

EU-Ansprechpartner

Zeitfracht Medien GmbH
Ferdinand-Jühlke-Straße 7|99095|Erfurt|DE
produktsicherheit@zeitfracht.de

Herstelleradresse

Elsevier Science & Technology
125 London Wall|EC2Y 5AS|London|GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Risk Factors for Psychosis
  • 1. Historical perspectives on psychosis risk
    CRISTINA MEI AND PATRICK D. MCGORRY
    2. Principles of risk, screening, and prevention in psychiatry
    EMMA SONESON, JESUS PEREZ, AND PETER B. JONES
    I - Risk paradigms
    3. At-risk mental states
    ALISON R. YUNG
    4. Subjective disturbances in emerging psychosis: basic symptoms and self-disturbances
    FRAUKE SCHULTZE-LUTTER, CHANTAL MICHEL, RAHEL FL EURUCKIGER, AND ANASTASIA THEODORIDOU
    5. Schizotypy, schizotypal personality, and psychosis risk
    NEUS BARRANTES-VIDAL, ANNA RACIOPPI, AND THOMAS R. KWAPIL
    6. Familial high risk and high-risk studies
    LIANA ROMANIUK, STELLA W.Y. CHAN, ALIX MACDONALD, JESSIKA E. SUSSMANN, ANDREW M. MCINTOSH, HEATHER C. WHALLEY, AND STEPHEN M. LAWRIE
    7. Psychotic-like experiences in the general population
    COLM HEALY AND MARY CANNON
    8. 22q11.2 deletion syndrome: a neurodevelopmental model of psychosis
    CORRADO SANDINI, STEPHAN ELIEZ, MAUDE SCHNEIDER, AND MARCO ARMANDO
    II - Specific areas and risk
    9. Neuroimaging studies in people at clinical high risk for psychosis
    GEORGE GIFFORD, ROB MCCUTCHEON, AND PHILIP MCGUIRE
    10. Genetic studies of psychosis
    HANNAH J. JONES, STANLEY ZAMMIT, AND JAMES T.R. WALTERS
    11. Immune processes and risk of psychosis
    ADAM AL-DIWANI AND THOMAS ARTHUR NICHOLLS POLLAK
    12. Neurochemical models of psychosis risk and onset
    DOMINIC OLIVER, GEMMA MODINOS, AND PHILIP MCGUIRE
    13. Clinical risk factors for psychosis
    ASWIN RATHEESH, JESSICA A. HARTMANN, AND BARNABY NELSON
    14. Cognitive risk factors for psychosis
    KELLY ALLOTT AND ASHLEIGH LIN
    15. Society and risk of psychosis
    CRAIG MORGAN, TESSA ROBERTS, BRIAN O. DONOGHUE, AND ANDREW THOMPSON
    16. Is there sufficient evidence that cannabis use is a risk factor for psychosis?
    MARCO COLIZZI AND SAGNIK BHATTACHARYYA
    III - Interventions
    17. The ethics of identifying and treating psychosis risk
    PAOLO CORSICO AND ILINA SINGH
    JEAN ADDINGTON, DANIJELA PISKULIC, DANIEL J. DEVOE, OLGA SANTESTEBAN-ECHARRI, AND JACQUELINE STOWKOWY
    19. Pharmacological intervention for people at risk of psychotic disorder
    E. BURKHARDT, K. LEOPOLD AND A. BECHDOLF
    20. International services for assessing and treating psychosis risk
    CHRISTY L.M. HUI, W.C. CHANG, SHERRY K.W. CHAN, EDWIN H.M. LEE, Y.N. SUEN, AND ERIC Y.H. CHEN
    21. New paradigms to study psychosis risk: clinical staging, pluripotency, and dynamic prediction
    RACHAEL SPOONER, JESSICA A. HARTMANN, PATRICK D. MCGORRY, AND BARNABY NELSON
    22. Future directions in risk research
    NIKOLAI ALBERT, LOUISE BIRKEDAL GLENTHØJ, AND MERETE NORDENTOFT